pharma
dog
News
when
Latest
Archive
by source
All Sources
Sources Page
Jobs
department
Clinical
Regulatory
Medical Affairs
Commercial
R&D / Discovery
Biostatistics / Data
Manufacturing / CMC
Market Access
therapeutic area
Oncology
Immunology
Neuroscience
Cardiovascular
Metabolic
Rare Disease
Infectious Disease
location & type
Remote Only
US Only
California
Massachusetts
Internships
Phase 3 Roles
All Jobs →
Drugs
by stage
Marketed
Phase 3
Phase 2
Phase 1
Preclinical
browse
Most catalysts
Recently active
All drugs →
Companies
Patent cliff
Calendar
what
Trial readouts
PDUFA dates
Approvals
Earnings
when
Upcoming
Month grid
Recently passed
◐
Sign In
Subscribe
home
jobs
news
search
Windward Bio AG · news · pharmadog
← back to Windward Bio AG
News mentioning Windward Bio AG
9
stories
6d
Windward Bio hits Nasdaq with $175M IPO, plus another $50M from Sanofi
endpoints
6d
Windward nets $175M IPO, bringing 2026 biotech debuts to 35
biospace
6d
Sanofi-backed Windward hits $225M IPO goal, as Rezera delays listing over ‘market conditions’
fiercebiotech
7d
Windward prices $175M IPO to advance China-licensed lung drugs
biopharma dive
10d
Sanofi-backed Windward breezes toward $204M IPO to fund respiratory pipeline from China
fiercebiotech
24d
Lycia leaps onto Nasdaq with upsized $318M IPO as Windward breezes toward listing
fiercebiotech
27d
Windward Bio files for Nasdaq IPO to fund China-derived assets and in-house R&D
endpoints
Sep 8, 26
Krazati withdrawal completed; Wegovy trial meets endpoint for kids ages 6 to 12
endpoints
May 4, 26
Windward Bio gets $165M to take China-derived drug into Phase 3 asthma trial
endpoints